Ontology highlight
ABSTRACT:
SUBMITTER: Garcia TB
PROVIDER: S-EPMC7066074 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Frontiers in oncology 20200305
WEE1 is a cell cycle and DNA damage response kinase that is emerging as a therapeutic target for cancer. AZD1775 is a small molecule inhibitor of WEE1, currently in early phase clinical trials as a single agent and in combination with more conventional anti-neoplastic agents. As resistance to kinase inhibitors is frequent, we sought to identify mechanisms of resistance to WEE1 inhibition in acute leukemia. We found that AZD1775 resistant cell lines are dependent upon increased HDAC activity for ...[more]